Literature DB >> 17545607

HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6.

Alan G Ramsay1, Melanie D Keppler, Mona Jazayeri, Gareth J Thomas, Maddy Parsons, Shelia Violette, Paul Weinreb, Ian R Hart, John F Marshall.   

Abstract

Enhanced expression levels of integrin alphavbeta6 have been linked to more aggressive invasive carcinoma cell behavior and poorer clinical prognosis. However, how alphavbeta6 determines invasion and the dynamics of integrin alphavbeta6 regulation in tumor cells are poorly understood. We have identified the 35-kDa HS1-associated protein X-1 (HAX-1) protein as a novel binding partner of the beta6 cytoplasmic tail using a yeast two-hybrid screen. We show that alphavbeta6-dependent migration is blocked following small interfering RNA (siRNA)-mediated depletion of HAX-1 in oral squamous cell carcinoma cell lines. Using both siRNA and membrane-permeable peptides, we show that alphavbeta6-dependent migration and invasion require HAX-1 to bind directly to beta6 and thereby regulate clathrin-mediated endocytosis of alphavbeta6 integrins. Progression of oral cancer is associated with enhanced expression of alphavbeta6 and HAX-1 proteins in patient tissue. This report establishes that integrin endocytosis is required for alphavbeta6-dependent carcinoma cell motility and invasion and suggests that this process is an important mechanism in cancer progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545607     DOI: 10.1158/0008-5472.CAN-07-0318

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

1.  Specific alterations of the HtrA2/HAX-1 ratio in the penumbra upon focal cerebral ischemia in mice.

Authors:  A Rami; A Langhagen
Journal:  Neurochem Res       Date:  2011-11-06       Impact factor: 3.996

Review 2.  Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation.

Authors:  Stacey J Coleman; Jennifer Watt; Prabhu Arumugam; Leonardo Solaini; Elisabeta Carapuca; Mohammed Ghallab; Richard P Grose; Hemant M Kocher
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Intrinsically disordered HAX-1 regulates Ca2+ cycling by interacting with lipid membranes and the phospholamban cytoplasmic region.

Authors:  Erik K Larsen; Daniel K Weber; Songlin Wang; Tata Gopinath; Daniel J Blackwell; Michael P Dalton; Seth L Robia; Jiali Gao; Gianluigi Veglia
Journal:  Biochim Biophys Acta Biomembr       Date:  2019-08-07       Impact factor: 3.747

Review 4.  Integrin trafficking at a glance.

Authors:  Rebecca E Bridgewater; Jim C Norman; Patrick T Caswell
Journal:  J Cell Sci       Date:  2012-08-15       Impact factor: 5.285

Review 5.  Integrins: masters and slaves of endocytic transport.

Authors:  Patrick T Caswell; Suryakiran Vadrevu; Jim C Norman
Journal:  Nat Rev Mol Cell Biol       Date:  2009-12       Impact factor: 94.444

Review 6.  Defining the role of integrin alphavbeta6 in cancer.

Authors:  A Bandyopadhyay; S Raghavan
Journal:  Curr Drug Targets       Date:  2009-07       Impact factor: 3.465

7.  HAX-1 overexpression, splicing and cellular localization in tumors.

Authors:  Alicja Trebinska; Alina Rembiszewska; Karolina Ciosek; Konrad Ptaszynski; Sebastian Rowinski; Jolanta Kupryjanczyk; Janusz A Siedlecki; Ewa A Grzybowska
Journal:  BMC Cancer       Date:  2010-03-02       Impact factor: 4.430

8.  Distant homologs of anti-apoptotic factor HAX1 encode parvalbumin-like calcium binding proteins.

Authors:  Katarzyna Kokoszyńska; Leszek Rychlewski; Lucjan S Wyrwicz
Journal:  BMC Res Notes       Date:  2010-07-15

Review 9.  Endocytosis and cancer.

Authors:  Ira Mellman; Yosef Yarden
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

10.  Organotypic modelling as a means of investigating epithelial-stromal interactions during tumourigenesis.

Authors:  Athina-Myrto Chioni; Richard Grose
Journal:  Fibrogenesis Tissue Repair       Date:  2008-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.